Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Targacept acquires Layton's Inversine

Executive Summary

Targacept (RJ Reynolds Tobacco spin-off exploring nicotinic-based drug targets) has acquired from Layton BioScience (researching neuronal cell therapy and other CNS treatments) its cardiovascular compound Inversine and plans to reformulate it for nervous system disorders.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Product Purchase
    • Includes Contract

Related Companies